An announcement from Mesoblast Limited ( (AU:MSB) ) is now available.
Mesoblast Limited has announced the commercial availability of Ryoncil® (remestemcel-L) in the United States, marking a significant milestone as the first FDA-approved mesenchymal stromal cell (MSC) therapy for any indication. Ryoncil® is designed to treat pediatric patients with steroid-refractory acute graft versus host disease (SR-aGvHD), a condition with high mortality rates. Mesoblast has established a patient access hub, MyMesoblast™, to assist with insurance coverage and financial assistance, ensuring broad access to this potentially life-saving therapy. The company is actively engaging with insurers to expand coverage, with nine commercial payers already on board, covering approximately 37 million lives in the U.S. This development reflects Mesoblast’s commitment to delivering innovative cellular medicines to patients in need.
More about Mesoblast Limited
Mesoblast Limited is a global leader in developing allogeneic cellular medicines for severe and life-threatening inflammatory conditions. The company utilizes its proprietary mesenchymal lineage cell therapy technology platform to create therapies that release anti-inflammatory factors, targeting multiple arms of the immune system to reduce inflammation. Mesoblast is committed to expanding its cell therapies for various indications and has established commercial partnerships in Japan, Europe, and China.
YTD Price Performance: -37.73%
Average Trading Volume: 244,610
Technical Sentiment Signal: Sell
Current Market Cap: $1.76B
For detailed information about MSB stock, go to TipRanks’ Stock Analysis page.